<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD04160000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P01009</UniProt_ID>
  <Seq_Length>418</Seq_Length>
  <Molecule_Weight>46737</Molecule_Weight>
  <KEGG_ID>hsa:5265</KEGG_ID>
  <Orthology_ID>K03984</Orthology_ID>
  <EBI_ID>EBI-986224</EBI_ID>
  <Function_Summary>Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin.Short peptide from AAT (SPAAT) is a reversible chymotrypsin inhibitor. It also inhibits elastase, but not trypsin. Its major physiological function is the protection of the lower respiratory tract against proteolytic destruction by human leukocyte elastase (HLE).</Function_Summary>
  <Pfam_ID>PF00079:Serpin</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>16</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>SPAAT</Alias>
      <Alias>Alpha-1-antiproteinase</Alias>
      <Alias>Alpha-1 protease inhibitor</Alias>
      <Alias>Short peptide from AAT</Alias>
      <Alias>Serpin A1</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any protease or peptidase.</Detail>
      <Keyword>Protease binding</Keyword>
      <Ontology_ID>GO:0002020</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Stops, prevents or reduces the activity of serine-type endopeptidases, enzymes that catalyze the hydrolysis of nonterminal peptide bonds in a polypeptide chain; a serine residue (and a histidine residue) are at the active center of the enzyme.</Detail>
      <Keyword>Serine-type endopeptidase inhibitor activity</Keyword>
      <Ontology_ID>GO:0004867</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Stops, prevents or reduces the activity of a peptidase, any enzyme that catalyzes the hydrolysis peptide bonds.</Detail>
      <Keyword>Peptidase inhibitor activity</Keyword>
      <Ontology_ID>GO:0030414</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>63</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>112</Position>
      <Original>Pro</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>58</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>109</Position>
      <Original>Thr</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>92</Position>
      <Original>Thr</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>386</Position>
      <Original>Pro</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>247</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>26</Position>
      <Original>Asp</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>172</Position>
      <Original>Gly</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>65</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>139</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>400</Position>
      <Original>Glu</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>280</Position>
      <Original>Asp</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>387</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>116</Position>
      <Original>Ile</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>366</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>415</Position>
      <Original>Pro</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>365</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>382</Position>
      <Original>Met</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>69</Position>
      <Original>Ser</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>393</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>237</Position>
      <Original>Val</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>91</Position>
      <Original>Gly</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>288</Position>
      <Original>Glu</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>172</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>360</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>354</Position>
      <Original>Ser</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>4</Position>
      <Original>Ser</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>125</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>386</Position>
      <Original>Pro</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>77</Position>
      <Original>Ser</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>180</Position>
      <Original>Gln</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>228</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>84</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>37</Position>
      <Original>Thr</Original>
      <Variation>Ala</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The sequential process in which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers.</Detail>
      <Keyword>Blood coagulation</Keyword>
      <Ontology_ID>GO:0007596</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>An acute inflammatory response that involves non-antibody proteins whose concentrations in the plasma increase in response to infection or injury of homeothermic animals.</Detail>
      <Keyword>Acute-phase response</Keyword>
      <Ontology_ID>GO:0006953</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.</Detail>
      <Keyword>Platelet activation</Keyword>
      <Ontology_ID>GO:0030168</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The regulated exocytosis of secretory granules containing preformed mediators such as histamine and serotonin by a platelet.</Detail>
      <Keyword>Platelet degranulation</Keyword>
      <Ontology_ID>GO:0002576</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The stopping of bleeding (loss of body fluid) or the arrest of the circulation to an organ or part.</Detail>
      <Keyword>Hemostasis</Keyword>
      <Ontology_ID>GO:0007599</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the hydrolysis of a peptide bond or bonds within a protein.</Detail>
      <Keyword>Regulation of proteolysis</Keyword>
      <Ontology_ID>GO:0030162</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>256</Position>
      <PTM_Type>S-cysteinyl cysteine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MPSSVSWGILLLAGLCCLVPVSLAEDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAFAMLSLGTKADTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGLKLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTVFALVNYIFFKGKWERPFEVKDTEEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLENELTHDIITKFLENEDRRSASLHLPKLSITGTYDLKSVLGQLGITKVFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK</Protein_Seq>
    <DNA_Seq>ACAATGACTCCTTTCGGTAAGTGCAGTGGAAGCTGTACACTGCCCAGGCAAAGCGTCCGGGCAGCGTAGGCGGGCGACTCAGATCCCAGCCAGTGGACTTAGCCCCTGTTTGCTCCTCCGATAACTGGGGTGACCTTGGTTAATATTCACCAGCAGCCTCCCCCGTTGCCCCTCTGGATCCACTGCTTAAATACGGACGAGGACAGGGCCCTGTCTCCTCAGCTTCAGGCACCACCACTGACCTGGGACAGTGAATCGACAATGCCGTCTTCTGTCTCGTGGGGCATCCTCCTGCTGGCAGGCCTGTGCTGCCTGGTCCCTGTCTCCCTGGCTGAGGATCCCCAGGGAGATGCTGCCCAGAAGACAGATACATCCCACCATGATCAGGATCACCCAACCTTCAACAAGATCACCCCCAACCTGGCTGAGTTCGCCTTCAGCCTATACCGCCAGCTGGCACACCAGTCCAACAGCACCAATATCTTCTTCTCCCCAGTGAGCATCGCTACAGCCTTTGCAATGCTCTCCCTGGGGACCAAGGCTGACACTCACGATGAAATCCTGGAGGGCCTGAATTTCAACCTCACGGAGATTCCGGAGGCTCAGATCCATGAAGGCTTCCAGGAACTCCTCCGTACCCTCAACCAGCCAGACAGCCAGCTCCAGCTGACCACCGGCAATGGCCTGTTCCTCAGCGAGGGCCTGAAGCTAGTGGATAAGTTTTTGGAGGATGTTAAAAAGTTGTACCACTCAGAAGCCTTCACTGTCAACTTCGGGGACACCGAAGAGGCCAAGAAACAGATCAACGATTACGTGGAGAAGGGTACTCAAGGGAAAATTGTGGATTTGGTCAAGGAGCTTGACAGAGACACAGTTTTTGCTCTGGTGAATTACATCTTCTTTAAAGGCAAATGGGAGAGACCCTTTGAAGTCAAGGACACCGAGGAAGAGGACTTCCACGTGGACCAGGTGACCACCGTGAAGGTGCCTATGATGAAGCGTTTAGGCATGTTTAACATCCAGCACTGTAAGAAGCTGTCCAGCTGGGTGCTGCTGATGAAATACCTGGGCAATGCCACCGCCATCTTCTTCCTGCCTGATGAGGGGAAACTACAGCACCTGGAAAATGAACTCACCCACGATATCATCACCAAGTTCCTGGAAAATGAAGACAGAAGGTCTGCCAGCTTACATTTACCCAAACTGTCCATTACTGGAACCTATGATCTGAAGAGCGTCCTGGGTCAACTGGGCATCACTAAGGTCTTCAGCAATGGGGCTGACCTCTCCGGGGTCACAGAGGAGGCACCCCTGAAGCTCTCCAAGGCCGTGCATAAGGCTGTGCTGACCATCGACGAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATCCCCCCCGAGGTCAAGTTCAACAAACCCTTTGTCTTCTTAATGATTGAACAAAATACCAAGTCTCCCCTCTTCATGGGAAAAGTGGTGAATCCCACCCAAAAATAACTGCCTCTCGCTCCTCAACCCCTCCCCTCCATCCCTGGCCCCCTCCCTGGATGACATTAAAGAAGGGTTGAGCTGGTCCCTGCCTGCATGTGACTGTAAATCCCTCCCATGTTTTCTCTGAGTCTCCCTTTGCCTGCTGAGGCTGTATGTGGGCTCCAGGTAACAGTGCTGTCTTCGGGCCCCCTGAACTGTGTTCATGGAGCATCTGGCTGGGTAGGCACATGCTGGGCTTGAATCCAGGGGGGACTGAATCCTCAGCTTACGGACCTGGGCCCATCTGTTTCTGGAGGGCTCCAGTCTTCCTTGTCCTGTCTTGGAGTCCCCAAGAAGGAATCACAGGGGAGGAACCAGATACCAGCCATGACCCCAGGCTCCACCAAGCATCTTCATGTCCCCCTGCTCATCCCCCACTCCCCCCCACCCAGAGTTGCTCATCCTGCCAGGGCTGGCTGTGCCCACCCCAAGGCTGCCCTCCTGGGGGCCCCAGAACTGCCTGATCGTGCCGTGGCCCAGTTTTGTGGCATCTGCAGCAACACAAGAGAGAGGACAATGTCCTCCTCTTGACCCGCTGTCACCTAACCAGACTCGGGCCCTGCACCTCTCAGGCACTTCTGGAAAATGACTGAGGCAGATTCTTCCTGAAGCCCATTCTCCATGGGGCAACAAGGACACCTATTCTGTCCTTGTCCTTCCATCGCTGCCCCAGAAAGCCTCACATATCTCCGTTTAGAATCAGGTCCCTTCTCCCCAGATGAAGAGGAGGGTCTCTGCTTTGTTTTCTCTATCTCCTCCTCAGACTTGACCAGGCCCAGCAGGCCCCAGAAGACCATTACCCTATATCCCTTCTCCTCCCTAGTCACATGGCCATAGGCCTGCTGATGGCTCAGGAAGGCCATTGCAAGGACTCCTCAGCTATGGGAGAGGAAGCACATCACCCATTGACCCCCGCAACCCCTCCCTTTCCTCCTCTGAGTCCCGACTGGGGCCACATGCAGCCTGACTTCTTTGTGCCTGTTGCTGTCCCTGCAGTCTTCAGAGGGCCACCGCAGCTCCAGTGCCACGGCAGGAGGCTGTTCCTGAATAGCCCCTGTGGTAAGGGCCAGGAGAGTCCTTCCATCCTCCAAGGCCCTGCTAAAGGACACAGCAGCCAGGAAGTCCCCTGGGCCCCTAGCTGAAGGACAGCCTGCTCCCTCCGTCTCTACCAGGAATGGCCTTGTCCTATGGAAGGCACTGCCCCATCCCAAACTAATCTAGGAATCACTGTCTAACCACTCACTGTCATGAATGTGTACTTAAAGGATGAGGTTGAGTCATACCAAATAGTGATTTCGATAGTTCAAAATGGTGAAATTAGCAATTCTACATGATTCAGTCTAATCAATGGATACCGACTGTTTCCCACACAAGTCTCCTGTTCTCTTAAGCTTACTCACTGACAGCCTTTCACTCTCCACAAATACATTAAAGATATGGCCATCACCAAGCCCCCTAGGATGACACCAGACCTGAGAGTCTGAAGACCTGGATCCAAGTTCTGACTTTTCCCCCTGACAGCTGTGTGACCTTCGTGAAGTCGCCAAACCTCTCTGAGCCCCAGTCATTGCTAGTAAGACCTGCCTTTGAGTTGGTATGATGTTCAAGTTAGATAACAAAATGTTTATACCCATTAGAACAGAGAATAAATAGAACTACATTTCTTGCA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Plasma</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular region</CellLocal>
      <Ontology_ID>GO:0005576</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Secreted</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular space</CellLocal>
      <Ontology_ID>GO:0005615</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Proteinaceous extracellular matrix</CellLocal>
      <Ontology_ID>GO:0005578</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Platelet alpha granule lumen</CellLocal>
      <Ontology_ID>GO:0031093</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>SERPINA1</Gene_Name>
    <Gene_Alias>AAT; PI</Gene_Alias>
    <Gene_ID>5265</Gene_ID>
    <Genbank_ACCN>NM_000295</Genbank_ACCN>
    <Protein_ACCN>NP_000286</Protein_ACCN>
    <HGNC_ID>8941</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/5265</Gene_URL>
    <UCSC_ID>uc001yda.1</UCSC_ID>
    <EMBL_ID>ENSG00000197249</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P00772</Uniprot_ID>
      <Gene_Name>CELA1</Gene_Name>
      <EBI_ID>EBI-986248</EBI_ID>
      <PPI_EBI_URL>EBI-986224,EBI-986248</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P71213</Uniprot_ID>
      <Gene_Name>espB</Gene_Name>
      <EBI_ID>EBI-2615322</EBI_ID>
      <PPI_EBI_URL>EBI-986224,EBI-2615322</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P01009</Uniprot_ID>
      <Gene_Name>SERPINA1</Gene_Name>
      <EBI_ID>EBI-986385</EBI_ID>
      <PPI_EBI_URL>EBI-986224,EBI-986385</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Fibromuscular Dysplasia</Disease_Name>
      <Disease_Detail>Fibromatosis</Disease_Detail>
      <Disease_DB>FBR032</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fibromuscular_dysplasia?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Siderosis</Disease_Name>
      <Disease_Detail>Siderosis</Disease_Detail>
      <Disease_DB>SDR002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/siderosis?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fibromyalgia</Disease_Name>
      <Disease_Detail>Fibromyalgia</Disease_Detail>
      <Disease_DB>FBR047</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fibromyalgia?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Congenital Granular Cell Tumor</Disease_Name>
      <Disease_Detail>Congenital Granular Cell Tumor</Disease_Detail>
      <Disease_DB>CNG022</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/congenital_granular_cell_tumor?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemorrhagic Diathesis Due to Antithrombin Pittsburgh</Disease_Name>
      <Disease_Detail>Hemorrhagic Disease</Disease_Detail>
      <Disease_DB>HMR040</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemorrhagic_diathesis_due_to_antithrombin_pittsburgh_3?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Boutonneuse Fever</Disease_Name>
      <Disease_Detail>Boutonneuse Fever</Disease_Detail>
      <Disease_DB>BTN002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/boutonneuse_fever?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Granular Cell Tumor</Disease_Name>
      <Disease_Detail>Granular Cell Tumor</Disease_Detail>
      <Disease_DB>GRN010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/granular_cell_tumor?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Panniculitis</Disease_Name>
      <Disease_Detail>Panniculitis</Disease_Detail>
      <Disease_DB>PNN001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/panniculitis?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pulmonary Emphysema</Disease_Name>
      <Disease_Detail>Pulmonary Emphysema</Disease_Detail>
      <Disease_DB>PLM034</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pulmonary_emphysema?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemorrhagic Disease Due to Alpha-1-Antitrypsin Pittsburgh Mutation</Disease_Name>
      <Disease_Detail>Hemorrhagic Disease</Disease_Detail>
      <Disease_DB>HMR041</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemorrhagic_disease_due_to_alpha_1_antitrypsin_pittsburgh_mutation_2?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Spontaneous Pneumothorax</Disease_Name>
      <Disease_Detail>Spontaneous Pneumothorax</Disease_Detail>
      <Disease_DB>SPN183</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/spontaneous_pneumothorax?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hepatic Tuberculosis</Disease_Name>
      <Disease_Detail>Hepatic Tuberculosis</Disease_Detail>
      <Disease_DB>HPT008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hepatic_tuberculosis?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Blastoma</Disease_Name>
      <Disease_Detail>Blastoma</Disease_Detail>
      <Disease_DB>BLS003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/blastoma?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Tuberculosis</Disease_Name>
      <Disease_Detail>Tuberculosis</Disease_Detail>
      <Disease_DB>TBR010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/tuberculosis?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Emphysema-Cirrhosis, Due to Aat Deficiency</Disease_Name>
      <Disease_Detail>Emphysema-Cirrhosis, Due to Aat Deficiency</Disease_Detail>
      <Disease_DB>EMP008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/emphysema_cirrhosis_due_to_aat_deficiency?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pleuropulmonary Blastoma</Disease_Name>
      <Disease_Detail>Pleuropulmonary Blastoma</Disease_Detail>
      <Disease_DB>PLR004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pleuropulmonary_blastoma?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Mycobacterium Abscessus</Disease_Name>
      <Disease_Detail>Mycobacterium Abscessus</Disease_Detail>
      <Disease_DB>MYC013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/mycobacterium_abscessus?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Alpha-1-Antichymotrypsin Deficiency</Disease_Name>
      <Disease_Detail>Alpha-1-Antichymotrypsin Deficiency</Disease_Detail>
      <Disease_DB>ALP044</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/alpha_1_antichymotrypsin_deficiency?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Alpha 1-Antitrypsin Deficiency</Disease_Name>
      <Disease_Detail>Alpha 1-Antitrypsin Deficiency</Disease_Detail>
      <Disease_DB>ALP007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/alpha_1_antitrypsin_deficiency?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Chronic Obstructive Pulmonary Disease</Disease_Name>
      <Disease_Detail>Chronic Obstructive Pulmonary Disease</Disease_Detail>
      <Disease_DB>CHR409</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/chronic_obstructive_pulmonary_disease?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Emphysema Due to Aat Deficiency</Disease_Name>
      <Disease_Detail>Emphysema Due to Aat Deficiency</Disease_Detail>
      <Disease_DB>EMP007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/emphysema_due_to_aat_deficiency?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Protein-Losing Enteropathy</Disease_Name>
      <Disease_Detail>Protein-Losing Enteropathy</Disease_Detail>
      <Disease_DB>PRT019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/protein_losing_enteropathy?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Liver Disease</Disease_Name>
      <Disease_Detail>Liver Disease</Disease_Detail>
      <Disease_DB>LVR013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/liver_disease?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diverticulitis</Disease_Name>
      <Disease_Detail>Diverticulitis</Disease_Detail>
      <Disease_DB>DVR002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diverticulitis?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Granulosa Cell Tumor of the Ovary</Disease_Name>
      <Disease_Detail>Granulosa Cell Tumor of the Ovary</Disease_Detail>
      <Disease_DB>GRN022</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/granulosa_cell_tumor_of_the_ovary?search=SERPINA1#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>UNCLEAVED ALPHA-1-ANTITRYPSIN</PDB_Title>
      <PDB_ID>1ATU</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ATU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The native strains in the hydrophobic core and flexible reactive loop of a serine protease inhibitor: crystal structure of an uncleaved alpha1-antitrypsin at 2.7 A.</PubMed_Title>
      <Author>Ryu, S.E., et al.</Author>
      <Journal>Structure(1996)4:1181-1192</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8939743?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE S VARIANT OF HUMAN ALPHA1-ANTITRYPSIN, STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM</PDB_Title>
      <PDB_ID>7API</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=7API</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The S variant of human alpha 1-antitrypsin, structure and implications for function and metabolism.</PubMed_Title>
      <Author>Engh, R., et al.</Author>
      <Journal>Protein Eng.(1989)2:407-415</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/2785270?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Gly117Phe Alpha1-Antitrypsin</PDB_Title>
      <PDB_ID>3DRU</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DRU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic and cellular characterisation of two mechanisms stabilising the native fold of alpha1-antitrypsin: implications for disease and drug design.</PubMed_Title>
      <Author>Gooptu, B., et al.</Author>
      <Journal>J.Mol.Biol.(2009)387:857-868</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19232354?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CLEAVED ALPHA-1-ANTITRYPSIN POLYMER</PDB_Title>
      <PDB_ID>1QMB</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1QMB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A 2.6A Structure of a Serpin Polymer and Implications for Conformational Disease</PubMed_Title>
      <Author>Huntington, J.A., et al.</Author>
      <Journal>J.Mol.Biol.(1999)293:449</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10543942?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Interactions causing the kinetic trap in serpin protein folding</PDB_Title>
      <PDB_ID>1IZ2</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IZ2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Interactions causing the kinetic trap in serpin protein folding</PubMed_Title>
      <Author>Im, H., et al.</Author>
      <Journal>J.BIOL.CHEM.(2002)277:46347-46354</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12244055?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Active site distortion is sufficient for proteinase inhibit second crystal structure of covalent serpin-proteinase complex</PDB_Title>
      <PDB_ID>2D26</PDB_ID>
      <Resolution>3.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2D26</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Active Site Distortion Is Sufficient for Proteinase Inhibition by Serpins: Structure of the covalent complex of alpha 1-proteinase inhibitor with porcine pancreatic elastase</PubMed_Title>
      <Author>Dementiev, A., et al.</Author>
      <Journal>J.Biol.Chem.(2006)281:3452-3457</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16321984?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of alpha-1-antitrypsin complexed with citrate</PDB_Title>
      <PDB_ID>3CWM</PDB_ID>
      <Resolution>2.51</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CWM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Preventing serpin aggregation: The molecular mechanism of citrate action upon antitrypsin unfolding.</PubMed_Title>
      <Author>Pearce, M.C., et al.</Author>
      <Journal>Protein Sci.(2008)17:2127-2133</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18780818?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF A1PI-PITTSBURGH IN THE NATIVE CONFORMATION</PDB_Title>
      <PDB_ID>1OO8</PDB_ID>
      <Resolution>2.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1OO8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Canonical inhibitor-like interactions explain reactivity of alpha1-proteinase inhibitor Pittsburgh and antithrombin with proteinases</PubMed_Title>
      <Author>Dementiev, A., et al.</Author>
      <Journal>J.Biol.Chem.(2003)278:37881-37887</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12860985?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Intact recombined alpha1-antitrypsin mutant PHE 51 to LEU</PDB_Title>
      <PDB_ID>1PSI</PDB_ID>
      <Resolution>2.92</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1PSI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Inhibitory conformation of the reactive loop of alpha 1-antitrypsin.</PubMed_Title>
      <Author>Elliott, P.R., et al.</Author>
      <Journal>Nat.Struct.Biol.(1996)3:676-681</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8756325?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF CLEAVED ANTITRYPSIN POLYMER</PDB_Title>
      <PDB_ID>1D5S</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1D5S</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Cleaved antitrypsin polymers at atomic resolution.</PubMed_Title>
      <Author>Dunstone, M.A., et al.</Author>
      <Journal>Protein Sci.(2000)9:417-420</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10716194?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>2.2 Angstrom Crystal Structure of Thr114Phe Alpha1-Antitrypsin</PDB_Title>
      <PDB_ID>3DRM</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DRM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic and cellular characterisation of two mechanisms stabilising the native fold of alpha1-antitrypsin: implications for disease and drug design.</PubMed_Title>
      <Author>Gooptu, B., et al.</Author>
      <Journal>J.Mol.Biol.(2009)387:857-868</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19232354?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>ALPHA1-ANTITRYPSIN</PDB_Title>
      <PDB_ID>1KCT</PDB_ID>
      <Resolution>3.46</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1KCT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of an uncleaved alpha 1-antitrypsin reveals the conformation of its inhibitory reactive loop.</PubMed_Title>
      <Author>Song, H.K., et al.</Author>
      <Journal>FEBS Lett.(1995)377:150-154</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8543039?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>2.0 ANGSTROM STRUCTURE OF INTACT ALPHA-1-ANTITRYPSIN: A CANONICAL TEMPLATE FOR ACTIVE SERPINS</PDB_Title>
      <PDB_ID>1QLP</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1QLP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Topography of a 2.0 A Structure of Alpha1-Antitrypsin Reveals Targets for Rational Drug Design to Prevent Conformational Disease.</PubMed_Title>
      <Author>Elliott, P.R., et al.</Author>
      <Journal>Protein Sci.(2000)9:1274</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10933492?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NON-COVALENT COMPLEX BETWEEN ALPHA-1-PI-PITTSBURGH AND S195A TRYPSIN</PDB_Title>
      <PDB_ID>1OPH</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1OPH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Canonical inhibitor-like interactions explain reactivity of alpha1-proteinase inhibitor Pittsburgh and antithrombin with proteinases</PubMed_Title>
      <Author>Dementiev, A., et al.</Author>
      <Journal>J.Biol.Chem.(2003)278:37881-37887</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12860985?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of an alpha-1-antitrypsin trimer</PDB_Title>
      <PDB_ID>3T1P</PDB_ID>
      <Resolution>3.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3T1P</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of a domain-swapped trimer reveals the molecular basis of 1-antitrypsin deficiency</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>THE S VARIANT OF HUMAN ALPHA1-ANTITRYPSIN, STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM</PDB_Title>
      <PDB_ID>9API</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=9API</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The S variant of human alpha 1-antitrypsin, structure and implications for function and metabolism.</PubMed_Title>
      <Author>Engh, R., et al.</Author>
      <Journal>Protein Eng.(1989)2:407-415</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/2785270?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of alpha-1-antitrypsin, crystal form A</PDB_Title>
      <PDB_ID>2QUG</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2QUG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Preventing serpin aggregation: The molecular mechanism of citrate action upon antitrypsin unfolding.</PubMed_Title>
      <Author>Pearce, M.C., et al.</Author>
      <Journal>Protein Sci.(2008)17:2127-2133</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18780818?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cleaved antitrypsin with P10 Pro, and P9-P6 Asp</PDB_Title>
      <PDB_ID>3NDD</PDB_ID>
      <Resolution>1.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3NDD</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The loop-sheet mechanism of serpin polymerization tested by reactive center loop mutations</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>A 2.1 ANGSTROM STRUCTURE OF AN UNCLEAVED ALPHA-1-ANTITRYPSIN SHOWS VARIABILITY OF THE REACTIVE CENTER AND OTHER LOOPS</PDB_Title>
      <PDB_ID>1HP7</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HP7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A 2.1 A resolution structure of an uncleaved alpha(1)-antitrypsin shows variability of the reactive center and other loops.</PubMed_Title>
      <Author>Kim, S., et al.</Author>
      <Journal>J.Mol.Biol.(2001)306:109-119</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11178897?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cleaved antitrypsin with P8-P6 Asp</PDB_Title>
      <PDB_ID>3NDF</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3NDF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The loop-sheet mechanism of serpin polymerization tested by reactive center loop mutations</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF A SERPIN:PROTEASE COMPLEX</PDB_Title>
      <PDB_ID>1EZX</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1EZX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of a serpin-protease complex shows inhibition by deformation.</PubMed_Title>
      <Author>Huntington, J.A., et al.</Author>
      <Journal>Nature(2000)407:923-926</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11057674?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE S VARIANT OF HUMAN ALPHA1-ANTITRYPSIN, STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM</PDB_Title>
      <PDB_ID>8API</PDB_ID>
      <Resolution>3.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=8API</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The S variant of human alpha 1-antitrypsin, structure and implications for function and metabolism.</PubMed_Title>
      <Author>Engh, R., et al.</Author>
      <Journal>Protein Eng.(1989)2:407-415</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/2785270?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>1.8 Angstrom structure of intact native wild-type alpha-1-antitrypsin</PDB_Title>
      <PDB_ID>3NE4</PDB_ID>
      <Resolution>1.81</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3NE4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Therapeutic target-site variability in [alpha]1-antitrypsin characterized at high resolution</PubMed_Title>
      <Author>Patschull, A.O., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.F(2011)67:1492-1497</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22139150?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of alpha-1-antitrypsin, crystal form B</PDB_Title>
      <PDB_ID>3CWL</PDB_ID>
      <Resolution>2.44</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CWL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Preventing serpin aggregation: The molecular mechanism of citrate action upon antitrypsin unfolding.</PubMed_Title>
      <Author>Pearce, M.C., et al.</Author>
      <Journal>Protein Sci.(2008)17:2127-2133</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18780818?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04610</Pathway_ID>
      <Pathway_Title>Complement and coagulation cascades</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Multi-domain proteins (alpha and beta)</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.f.b.b.b.e.html</SCOP_URL>
    <CATH_Class>Class 3: Mixed Alpha-Beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1atu</CATH_URL>
  </Fold>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD04162001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04162002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04162003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04162004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04162005</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04162006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04162007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04162008</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04162009</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04162010</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04162011</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04162012</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04162013</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04162014</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04162015</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04162016</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>